

Craig R Lee

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8902212/craig-r-lee-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

4,834
citations

41
h-index

68
g-index

113
ext. papers

5,548
ext. citations

4.8
avg. IF

5.25
L-index

#	Paper	IF	Citations
100	Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 251-63		585
99	Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 178-91	15.9	208
98	Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 497-504	15.1	192
97	Vasopressin: a new target for the treatment of heart failure. <i>American Heart Journal</i> , 2003 , 146, 9-18	4.9	171
96	Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. <i>Circulation Research</i> , 2006 , 99, 442-50	15.7	161
95	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 181-191	5	156
94	Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. <i>Human Molecular Genetics</i> , 2006 , 15, 1640-9	5.6	152
93	Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 227-34	1.9	141
92	Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , 2010 , 48, 331-41	5.8	137
91	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. <i>FASEB Journal</i> , 2010 , 24, 3770-81	0.9	116
90	beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 127-37	6.1	106
89	Epoxyeicosanoids promote organ and tissue regeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 13528-33	11.5	102
88	Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. <i>FASEB Journal</i> , 2011 , 25, 703-13	0.9	100
87	Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H142-51	5.2	95
86	Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 22-9	4	92
85	Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. <i>FASEB Journal</i> , 2011 , 25, 3436-47	0.9	90
84	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 191-200	6.1	89

83	The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. <i>Human Molecular Genetics</i> , 2005 , 14, 2829-37	5.6	82
82	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. <i>Pharmacogenomics</i> , 2009 , 10, 1799-817	2.6	81
81	Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. <i>Atherosclerosis</i> , 2012 , 222, 530-6	3.1	77
80	CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 349-58	1.9	74
79	Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 84-91	2.9	73
78	Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 52-60	6.1	69
77	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 664-674	6.1	64
76	Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. <i>American Journal of Medicine</i> , 2017 , 130, 517-524	2.4	57
75	The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e110162	3.7	57
74	Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity. <i>Journal of Lipid Research</i> , 2014 , 55, 2124-36	6.3	56
73	CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. <i>Hypertension</i> , 2014 , 64, 1352-61	8.5	56
72	The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. <i>Clinical and Translational Science</i> , 2017 , 10, 143-146	4.9	54
71	Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. <i>Atherosclerosis</i> , 2013 , 227, 442-8	3.1	54
70	Epoxyeicosatrienoic acids and cardioprotection: the road to translation. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 74, 199-208	5.8	51
69	Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. <i>European Journal of Clinical Pharmacology</i> , 2003 , 58, 791-4	2.8	46
68	Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. <i>Hypertension</i> , 2011 , 57, 116-22	8.5	45
67	Evaluation of cytochrome P450C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 562-71	6.1	45
66	Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers. <i>American Journal of Cardiology</i> , 2012 , 109, 651-7	3	43

65	Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 145-60	1.9	42
64	Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002069	5.2	41
63	Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. <i>Journal of Lipid Research</i> , 2016 , 57, 109-19	6.3	41
62	A renaissance in pharmacy education at the University of North Carolina at Chapel Hill. <i>North Carolina Medical Journal</i> , 2014 , 75, 48-52	0.6	41
61	Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. <i>Pharmacogenomics</i> , 2007 , 8, 1369-83	2.6	41
60	Difficulties in anticoagulation management during coadministration of warfarin and rifampin. <i>Pharmacotherapy</i> , 2001 , 21, 1240-6	5.8	41
59	Relationship of Clinical Signs and Chest-X Ray Congestion to the Efficacy of Digoxin in Patients with Chronic Heart Failure: A Retrospective Analysis of the Digoxin Investigation Group Trial. <i>Journal of Cardiac Failure</i> , 2006 , 12, S87-S88	3.3	37
58	Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012 , 302, E500-9	6	36
57	Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 620-8	1.9	36
56	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. <i>Clinical and Translational Science</i> , 2017 , 10, 443-454	4.9	34
55	Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. <i>Prostaglandins and Other Lipid Mediators</i> , 2012 , 99, 68-78	3.7	34
54	Resolvin Infectious Inflammation by Targeting the Host Response. <i>New England Journal of Medicine</i> , 2015 , 373, 2183-5	59.2	33
53	Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 647-652	9.4	29
52	Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. <i>American Heart Journal</i> , 2007 , 153, 1074-80	4.9	29
51	Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. <i>PLoS ONE</i> , 2013 , 8, e61244	3.7	28
50	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. <i>Genetics in Medicine</i> , 2020 , 22, 160-169	8.1	28
49	Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. <i>Pharmacogenomics</i> , 2015 , 16, 303-13	2.6	27
48	Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. <i>FASEB Journal</i> , 2014 , 28, 2915-31	0.9	27

47	Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. <i>Pharmacotherapy</i> , 2003 , 23, 720-5	5.8	27
46	CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. <i>Pharmacogenomics</i> , 2017 , 18, 1155-1166	2.6	24
45	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 1944-1954	2.2	23
44	NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities study. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 891-9	1.9	22
43	Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015 , 11, 1797-807	6	20
42	Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis. <i>Prostaglandins and Other Lipid Mediators</i> , 2016 , 125, 19-29	3.7	19
41	Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. <i>Journal of Clinical Investigation</i> , 2017 , 127, 670-680	15.9	19
40	Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. <i>Pharmacogenomics</i> , 2018 , 19, 1039-1046	2.6	18
39	Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. <i>American Journal of Pathology</i> , 2017 , 187, 2895-2911	5.8	18
38	Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019 , 98, 106590	1.7	17
37	Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. <i>Prostaglandins and Other Lipid Mediators</i> , 2013 , 104-105, 67-73	3.7	17
36	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>Value in Health</i> , 2020 , 23, 61-73	3.3	17
35	Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. <i>Prostaglandins and Other Lipid Mediators</i> , 2015 , 120, 139-47	3.7	16
34	Warfarin dosing and the promise of pharmacogenomics. <i>Current Clinical Pharmacology</i> , 2007 , 2, 11-21	2.5	15
33	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	14
32	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , 2020 , 20, 724-735	3.5	11
31	The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. <i>Annals of Pharmacotherapy</i> , 2009 , 43, 2021-30	2.9	11
30	Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium. <i>Experimental Neurology</i> , 2016 , 279, 75-85	5.7	10

29	Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. <i>Pharmacogenomics</i> , 2018 , 19, 771-782	2.6	10
28	Surrogate end points in heart failure. <i>Annals of Pharmacotherapy</i> , 2002 , 36, 479-88	2.9	9
27	CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002441	5.2	9
26	Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2018 , 134, 24-31	3.7	9
25	High-impact articles related to the pharmacotherapeutic management of systolic heart failure. <i>Pharmacotherapy</i> , 2004 , 24, 1594-633	5.8	8
24	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 705-715	6.1	8
23	High-impact articles related to the management of heart failure: 2008 update. <i>Pharmacotherapy</i> , 2009 , 29, 82-120	5.8	7
22	Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. <i>Pharmacogenomics and Personalized Medicine</i> , 2020 , 13, 239-252	2.1	6
21	Warfarin initiation and the potential role of genomic-guided dosing. <i>Clinical Medicine and Research</i> , 2005 , 3, 205-6	1.4	5
20	Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 412-421	3.9	5
19	Response by Lee and Stouffer to Letter Regarding Article, "Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention". <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002258	5.2	5
18	Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. <i>Pharmacogenomics</i> , 2020 , 21, 431-441	2.6	4
17	A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty. <i>Future Cardiology</i> , 2019 , 15, 251-254	1.3	4
16	Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. <i>Prostaglandins and Other Lipid Mediators</i> , 2018 , 138, 15-22	3.7	3
15	Key Articles Relative to Cardiovascular Pharmacogenomics. <i>Pharmacotherapy</i> , 2009 , 29, 1110-1151	5.8	3
14	Implementation and Initial Evaluation of a Research and Scholarship Training Pathway in a Doctor of Pharmacy Curriculum. <i>American Journal of Pharmaceutical Education</i> , 2021 , 85, 8079	2.5	3
13	Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes. <i>Frontiers in Pharmacology</i> , 2021 , 12, 655320	5.6	3
12	Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. <i>Pharmacogenomics Journal</i> , 2018 , 18, 215-226	3.5	2

11	How-to guide for overcoming barriers of research and scholarship training in Pharm.D. and pharmacy residency programs. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021 , 4, 743-753	1.4	2
10	Logistical Challenges Associated With Implementing Precision Medicine. <i>JAMA Cardiology</i> , 2019 , 4, 1300-1306	16.2	1
9	Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 315-6	2.8	1
8	The essential research curriculum for doctor of pharmacy degree programs 2021. <i>JACCP Journal of the American College of Clinical Pharmacy</i> ,	1.4	1
7	Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024159	6	1
6	Effect of Gender on Clinical Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, 554-558	5.2	1
5	The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1261-1279	5.5	0
4	Highlights from recent advances in antiplatelet pharmacogenomics. <i>Personalized Medicine</i> , 2014 , 11, 135-138	2.2	
3	Research Highlights: Highlights from the latest articles in personalized cardiovascular medicine. <i>Personalized Medicine</i> , 2012 , 9, 363-366	2.2	
2	Low-Molecular-Weight Heparin Therapy in Acute Coronary Syndromes. <i>Hospital Pharmacy</i> , 2000 , 35, 955-963	16.3	
1	How-To Guide for Overcoming Barriers of Research and Scholarship Training in Pharm.D. and Pharmacy Residency Programs. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021 , 4, 743-753	1.4	